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ABSTRACT
Tenofovir was licensed for use in patients with
HIV in 2001 and since then has become a firmly
established anti-retroviral in both guidelines
and routine practice. Data have been
presented from many pivotal studies—
informing on its efficacy, use, and adverse
features—and there are also over 7.5 million
patient-years of experience to date. We explore
the data on this nucleotide reverse transcriptase
inhibitor in HIV presented since 2008—
focusing on efficacy, side effects, and utility.
Keywords: Efficacy; HIV; Tenofovir; Toxicity
INTRODUCTION
Tenofovir has become a fundamental
component of many human
immunodeficiency virus (HIV) anti-retroviral
regimens since its introduction in 2001. Its use
and supporting data were reviewed by Pozniak
[1] in 2008, and since then significantly more
data on efficacy, tolerability, and toxicities have
been acquired. Tenofovir disoproxil fumarate
(TDF) is soon to become generic in many
countries, and in forthcoming years may be
partially superseded by tenofovir alafenamide
(TAF), a pro-drug of tenofovir in the late stages
of development. It therefore seems timely to
review the further knowledge gained since 2008
on this nucleotide reverse transcriptase
inhibitor in HIV. This review is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
GLOBAL EXPERIENCE
AND POSITION IN GUIDELINES
As of the end of 2014, it is estimated that over
7.5 million person-years of tenofovir have been
Electronic supplementary material The online
version of this article (doi:10.1007/s40121-015-0070-1)
contains supplementary material, which is available to
authorized users.
A. Ustianowski (&)
Regional Infectious Diseases Unit, North
Manchester General Hospital, Manchester, UK
e-mail: andrew.ustianowski@pat.nhs.uk
J. E. Arends
University Medical Center Utrecht (UMCU),
Utrecht, The Netherlands
Infect Dis Ther (2015) 4:145–157
DOI 10.1007/s40121-015-0070-1
prescribed globally (personal communication,
Gilead Sciences, data on file). There is therefore
very extensive patient and physician experience
of this medication. It has also become a
recommended drug in all international
guidelines—as TDF tablets or as part of fixed-
dose combinations (FDCs): Truvada (TDF/
emtricitabine; Gilead Sciences, Inc.), Atripla
(TDF/emtricitabine/efavirenz; Bristol-Myers
Squibb & Gilead Sciences, Inc.); Eviplera/
Complera (TDF/emtricitabine/rilpivirine;
Gilead Sciences, Inc.); and Stribild (TDF/
emtricitabine/elvitegravir/cobicistat; Gilead
Sciences, Inc.). Many of the pivotal anti-
retroviral therapy (ART) studies undertaken in
the last few years have assessed regimens that
included TDF, and as a result much is
understood of the combination of this drug
with other currently available anti-retrovirals.
Some guidelines concurrently have become
more discriminating—not just listing preferred
and alternative drugs in each class but directly
drawing on the data available to recommend
specific drug combinations. The International
Antiviral Society (IAS)-USA guideline is one
such example [2].
EFFICACY
Over the years, TDF has been successfully used
in combination with the newer non-nucleoside
reverse-transcriptase inhibitors (NNRTIs),
protease inhibitors (PIs), and integrase
inhibitors (INSTIs), showing high rates of
undetectable serum HIV-RNA in clinical trials.
Though cohorts can provide some supportive
data on efficacy, their main use has been in
delineating toxicities and adverse events and
they will therefore be discussed predominately
in later sections. Much of the informative data
has been from studies in patients naı¨ve to ART,
though there have also been some important
switch studies published.
Naı¨ve Studies
The main naı¨ve studies of note have either
utilized TDF as part of the nucleoside/
nucleotide backbone for studies of third
agents; investigated the single-tablet regimens
(STRs) that have been developed which contain
TDF; or have specifically examined TDF
compared to other nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs)—
principally abacavir.
Studies Comparing NRTIs
In the latter area—TDF compared to other
NRTIs—the pivotal study since the last review
has been the ACTG 5202 trial (ClinicalTrials.gov
number, NCT00118898) [3, 4]. This placebo-
controlled, randomized study of 1857 patients
examined the time to virologic failure in
patients treated with Truvada compared to
Kivexa (abacavir/lamivudine; known as
Epzicom in North America; GlaxoSmithKline
Ltd.) in combination with either efavirenz or
ritonavir-boosted atazanavir. This study was
partially halted and unblinded (on the
instruction of the Data Safety Monitoring
Committee) as more virologic failures were
seen in those with a high baseline viral load
([100,000 copies/ml) receiving Kivexa versus
those receiving Truvada [hazard ratio of 2.33
(95% CI 1.46–3.72)]. Data on HLA-B5701 typing
and baseline genotypic resistance analyses were
not available in some subjects and this may
theoretically have partially contributed to these
results; however, a similar signal (favoring
Truvada at high viral loads) was also seen in
the randomized, open-label ASSERT study
(ClinicalTrials.gov number, NCT00549198)—
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comparing Truvada and Kivexa, each in
combination with efavirenz [5, 6].
Meta-analyses have been performed assessing
the question of the differential efficacy of
Truvada and Kivexa at high viral loads and
have produced variable results. Hill and Sawyer
[7] and Lee et al. [8] determined that Truvada
achieved greater virology success, while Cruciani
et al. [9] found no significant differences.
Tenofovir as an NRTI Backbone in Studies
of Other Anti-Retrovirals
Truvada has been the NRTI backbone most
commonly utilized in naı¨ve studies examining
the efficacy and utility of the newer anti-
retrovirals. Examples of such recent studies are
shown in Table 1 and many of the newer agents
still under development continue to be studied
primarily in combination with tenofovir/
emtricitabine.
The majority of these studies utilized TDF in
both arms and therefore give little insight into
the efficacy and utility of tenofovir as compared
to other NRTIs, but they do give a wealth of
encouraging data on the suitability of pairing
these third agents with this nucleotide reverse
transcriptase inhibitor—which can then be used
to inform clinical practice on which
combinations of anti-retroviral agents to use
in individual patients.
Table 1 Main naı¨ve anti-retroviral therapy studies informing guidelines and practice since 2008
New drug
class
Arms NRTI backbone References
Protease
inhibitors
Darunavir/r vs. lopinavir/r Truvada ARTEMIS
[82]
Atazanavir/r vs. lopinavir/r Truvada CASTLE [83]
INSTIs Raltegravir vs. efavirenz Truvada StartMrk [84]















NNRTIs Rilpivirine vs. efavirenz Truvada ECHO [10]
Rilpivirine vs. efavirenz NRTIs of investigator choice: Truvada (60%), Kivexa
(10%), Combivir (30%)
THRIVE [10]
Rilpivirine vs. efavirenz Truvada STAR [11]
Mixed Raltegravir vs. atazanavir/r vs.
darunavir/r
Truvada A-5250 [88]
bid twice daily, INSTIs integrase inhibitors, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, NNRTIs non-
nucleoside reverse transcriptase inhibitors, qd once daily, r ritonavir-boosted
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Tenofovir as Part of New Fixed-Dose
Combinations
Tenofovir has become an integral component of
many of the FDCs and STRs developed in recent
years. Atripla was licensed (in 2006 in the US
and 2007 in Europe) on the basis of switch
studies from efavirenz and Truvada, and
pharmacokinetic modeling and bioequivalence
assays.
Eviplera/Complera was licensed in 2011
on the basis of the ECHO/THRIVE
(ClinicalTrials.gov numbers, NCT00540449
and NCT00543725) data comparing rilpivirine
plus NRTIs and efavirenz plus NRTIs (100% of
patients in ECHO, and 60% of participants in
THRIVE received TDF/emtricitabine as their
backbone) [10]. Its utility as an STR was
assessed further in naı¨ve patients in the
randomized unblinded STAR study (Eviplera/
Complera vs. Atripla; ClinicalTrials.gov,
number NCT01309243) [11].
Stribild was licensed in 2012 in the US and
2013 in Europe, on the basis of blinded
comparisons to Atripla and to Truvada and
atazanavir/ritonavir (GS-102 [ClinicalTrials.gov,
number NCT01095796] and GS-103
[ClinicalTrials.gov, number NCT01106586]
studies, respectively) [12, 13].
As with the studies listed in the preceding
section, these trials reveal little on the efficacy
or utility of TDF itself compared to other NRTIs,
but do provide good data to support its use as
part of these STRs.
Switch Studies
There have been switch studies designed to
demonstrate data on the comparative efficacy
and utility of tenofovir. BICOMBO was an
open-label comparison of 333 patients
stable on abacavir/lamivudine-based therapy,
randomized to either remain on their present
regimen or switch to a TDF/emtricitabine-based
combination [14]. Treatment failure (and
adverse events leading to discontinuation) was
higher in those that remained on abacavir/
lamivudine compared to those switched
to TDF/emtricitabine. The SWIFT study
(ClinicaTrials.gov number, NCT00724711)
assessed a similar randomized open-label
switch for 311 patients on stable abacavir/
lamivudine and boosted PI regimen, with non-
inferiority shown between the two arms
(remaining on abacavir/lamivudine or
switching to TDF/emtricitabine) [15]. Similar
non-inferior results were seen in the 360
patients enrolled in the STEAL study
(ClinicaTrials.gov number, NCT00192634),
which examined switching stable patients’
NRTIs to either abacavir/lamivudine or TDF/
emtricitabine [16].
It must however be acknowledged that all
switch studies have inherent biases that may
influence results.
Other Knowledge Gained from Studies
We have also acquired data on the forgiveness
of TDF/emtricitabine/efavirenz (Atripla) in
terms of viral breakthrough and resistance
development in the FOTO study
(ClinicalTrials.gov number, NCT00414635)
[17]. It had been argued that the similar
(intracellular) half-lives of the active agents in
this combination would allow forgiveness of
missed doses and avoid significant ‘effective
monotherapy’ of agents with longer half-lives as
a result of poor adherence. Cohen et al. [17]
assessed the viral control in stable patients (with
CD4 [200 cells/ml) who had been well
controlled on daily TDF/emtricitabine/
efavirenz and who switched to taking the
Atripla Monday–Friday but missing dosing on
Saturdays and Sundays (FOTO is an acronym for
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Five On Two Off). Similar viral control (with no
excess in rebound or resistance) was seen
compared to those who continued daily
Atripla dosing. Though this dosing regimen is
not specifically advocated, it significantly helps
to inform discussion with patients on the
potential impact of missed or late doses.
Tenofovir and the combination of TDF/
emtricitabine have been heavily investigated
in pre-exposure prophylaxis (PrEP)—therapy to
at-risk HIV-negative individuals to prevent
acquisition of HIV. Though a full review of
this strategy is outside the scope of this paper,
significant protection was demonstrated for
TDF or TDF/emtricitabine in many settings
[18–21]. Topical (mainly vaginal) tenofovir has
also demonstrated efficacy [20, 22].
TOLERABILITY AND TOXICITY
In 2008, 7 years after its licensing as an anti-
retroviral, Pozniak [1] reported on the safety of
TDF and concluded that a considerable amount
of clinical data and experience supported the
favorable tolerability of TDF. With a further
7 years of clinical experience, it is timely to re-
review its safety profile.
General
Tenofovir disoproxil fumarate, and the FDCs
that contain this NRTI, are generally well
tolerated by HIV-infected patients with the
most reported adverse events being some
dizziness and gastro-intestinal discomfort (i.e.,
low-grade diarrhea and nausea), rarely
significant enough to cause discontinuation
[23, 24]. Furthermore, 7-year follow-up data of
TDF monotherapy in chronic hepatitis B (HBV)-
infected patients have demonstrated a very low
drug-related discontinuation rate of 0.5% [25].
Renal
The key potential toxicity of TDF remains renal
tubular dysfunction. This can vary from low-
grade plasma creatinine increases (with a
consequent drop in the estimated glomerular
filtration rate [eGFR]) to significant renal
tubular dysfunction and Fanconi’s syndrome.
Such renal adverse effects were already well
recognized by the time of Pozniak’s review in
2008 [1], but further data and understanding
have since been acquired.
The commencement of TDF may be
associated with an initial decline in eGFR and
actual glomerular filtration rate within the first
few months. However, long-term follow-up
studies (e.g., the extended phase-3 studies
GS903E [10 years] and GS934 [5 years]—
comparing TDF to either zidovudine or
stavudine [26–29]) have demonstrated that the
mean eGFR subsequently stabilizes. In the
combined 3-year renal analysis of the GS934
and GS903E studies, no patients discontinued
because of adverse renal events and there was
no apparent increased risk of clinically
significant renal dysfunction associated with
TDF [28]. Subsequently, large meta-analyses
have demonstrated a significantly greater loss
of renal function in those on TDF (as compared
to non-TDF-containing regimens), but only rare
severe renal dysfunction [30]. However, in those
who develop significant tenofovir-associated
renal impairment there is frequent, but not
universal, reversibility on TDF discontinuation
[31].
There are many other potential causes and
confounders for renal impairment in patients
commencing anti-retrovirals (e.g., age,
concomitant illnesses and medications) and
therefore the impact on renal physiology of
TDF in healthy HIV-negative subjects in PrEP
studies has been examined. Small declines in
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eGFR after TDF initiation were again seen [32,
33]. A drawback is the limited duration of TDF
use in these PreP studies to date, in conjunction
with a short follow-up time.
Fanconi’s syndrome remains a rare side effect
of TDF therapy. After initial case reports [34–
37], case series and cohorts have provided more
solid proof for this association. For example, the
US Food and Drug Administration examined
164 adverse event reports fulfilling the
definition of Fanconi’s syndrome [38]. It
became apparent that the majority of patients
were receiving a PI (83%, with 74% also on
ritonavir boosting) in conjunction with TDF.
Some further studies also suggested an
association between TDF-related renal tubular
dysfunction and boosted PI use [37, 39, 40].
The randomized ACTG 5202 study
(ClinicalTrials.gov number, NCT00118898)
demonstrated an increase in the calculated
creatinine clearance at week 96 in those
receiving TDF with efavirenz, with a drop only
being seen in those receiving TDF with boosted
atazanavir [41].
Though the potential mechanisms behind
such an association are still unclear, there are
plausible pathophysiologic interactions.
Tenofovir is eliminated via the kidney by a
combination of glomerular filtration and active
tubular secretion facilitated by multidrug-
resistant protein type 4 [42–45]. This latter
protein does not seem to be affected by the
PIs, however, they may increase net intestinal
absorption of tenofovir, and this may (in
theory) lead to higher renal tubular cell
tenofovir levels and thereby potentially
contribute to nephrotoxicity [46–48].
TDF Renal Toxicity in HBV
However, concomitant medications do not
appear to be a prerequisite for Fanconi’s
syndrome development with TDF. In HBV
mono-infection, Fanconi’s syndrome cases
have been reported, though potentially at
lower rates than in HIV-infected patients [49–
52]. Whether this may be partially related to
improved renal monitoring in these patients
(following lessons learnt from the HIV-infected
patients) is unclear.
Lesser degrees of renal dysfunction have also
been seen in HBV mono-infected individuals
treated with TDF. Buti et al. [25] summarized
7-year efficacy and safety data from the original
TDF-HBV registration trials incorporating 437
patients and reported only 1.7% where renal
function had been noticed to significantly alter.
However, only serum creatinine, serum
phosphate, and eGFR were utilized as measures
of TDF toxicity. Contrary, Tien et al. [53]
assessed the TmPO4 (maximal rate of tubular
reabsorption of phosphate)/GFR ratio in HBV-
infected patients treated for [18 months with
TDF and reported an increased risk of proximal
tubular dysfunction.
Renal Monitoring in Those on TDF
The above discrepant data illustrate the
potential importance of the methodology of
renal monitoring. There is no universally
accepted method of monitoring renal
physiology or detecting renal tubular
dysfunction in this clinical setting. It is clear
that eGFR measurement alone is not adequate
to exclude more subtle, but potentially severe,
changes in kidney physiology.
Increased phosphaturia, normoglycemic
glucosuria, and aminoaciduria are markers of
proximal tubular dysfunction, and periodic
evaluation for these may aid in the diagnosis
of incipient tubular injury. Maggi et al. [54]
evaluated TDF-induced tubular dysfunction in
patients randomly assigned to either a TDF- or
abacavir-containing regimen through analysis
of urinary excretion of phosphate and uric acid.
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Although there was no significant variation in
eGFR, there was a significant increase in urinary
excretion of phosphate in patients on TDF
compared to those on abacavir after 6 and
12 months. To date, no long-term follow-up
studies have yet reported on the development
of early tubular dysfunction markers over time
while on TDF.
Pregnancy and Breast Milk
There are only a very limited number of studies
evaluating the pharmacokinetic profile of TDF
during pregnancy. TDF has been shown to cross
the placenta resulting in significant fetal
concentrations (as measured by paired
maternal plasma and umbilical cord samples)
[55]. However, there appears to be no increased
rate of fetal abnormalities in studies nor in the
Anti-Retroviral Pregnancy Registry in those
receiving this NRTI [56]. Of 1800 reported
pregnancies where the mother had taken TDF,
no increased rates of congenital abnormalities
above controls have been seen. The number of
exposed women was expected to have been
sufficient to detect at least a 1.5-fold increase in
risk of overall birth defects and a twofold
increase in risk of birth defects in the more
common classes—cardiovascular and
genitourinary systems. A similar observation
was noted in the DART trial (controlled-
trials.com number, ISRCTN13968779) with no
increase in congenital, renal, or growth
abnormalities with in utero tenofovir exposure
[57].
To date, the main study evaluating TDF
concentrations in breast milk was performed
in Coˆte d’Ivoire in a small group of 5 women
with 16 breast milk samples [58]. TDF is
excreted in breast milk although in very small
concentrations (0.03% of the proposed oral
infant dose).
Bone
Compared to the general population, HIV-
infected patients are at increased risk of
developing osteoporosis and fractures [59, 60].
A meta-analysis of cross-sectional studies using
dual-energy X-ray absorptiometry to measure
bone mineral density (BMD) demonstrated
reduced BMD and increased rates of
osteoporosis in HIV-infected versus non-HIV-
infected patients (pooled odds ratios of 6.4 and
3.7, respectively) [59].
The etiology of osteoporosis in HIV-infected
patients is multifactorial with traditional risk
factors, such as hypogonadism, low vitamin D,
smoking, age, and low body weight being at
least partially responsible [61]. Low nadir CD4
cell counts have been associated with larger
declines in BMD [62]. It is probable that HIV-
related immune activation may also be a
causative factor, with cytokines such as OPG
and RANKL (associated with osteoclast
activation and bone resorption) being present
at higher concentrations in untreated HIV-
infected patients compared to those with
treated HIV or non-HIV-infected controls [63].
However, anti-retroviral agents have also
been implicated in causing osteoporosis [64–
66]—with several studies specifically focusing
on the potential association with TDF [27, 67,
68]. In the randomized ASSERT study, patients
on TDF had a significantly greater decline in hip
BMD compared to those in the abacavir arm
(-3.5% versus -2.2% at week 96) [5].
Furthermore, bone turnover markers like
P1NP, osteocalcin, and alkaline phosphatase
were increased in those receiving TDF
compared to those on abacavir at both week
48 and week 96 [5, 69]. Similarly, individuals
using TDF for PrEP demonstrated small but
statistically significant declines in BMD at the
total hip (0.8–1.1% at months 24–30) and
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femoral neck (1.51% at month 30) compared to
placebo [70, 71]. Long-term exposure to TDF
has also been shown to be associated with an
increased risk of osteoporotic fracture [72].
Overall, however, it appears that the main
impact of anti-retrovirals (including TDF) on
BMD is within the first 48 weeks of
commencement, with apparent stabilization
subsequently [73]. It is unclear whether the
impact is diminished in those already stabilized
on anti-retrovirals before switching to TDF (as
seen in the BICOMBO [14, 74] and STEAL
studies [75] ).
Switching away from NRTIs may help
reverse some of the loss in BMD—as seen in
the small GUSTA study (ClinicalTrials.gov
number, NCT01367210) [76]. Of 27 patients
(the majority treated with TDF), 13
switched to the non-NRTI combination of
maraviroc/darunavir/ritonavir and were noted
to have improvements in their proximal femur
BMD from baseline to week 48 (mean increase
of 2.06%), whilst those that did not switch had
a mean decrease (-2.77%).
Several mechanisms have been postulated as
to how anti-retrovirals could be associated with
loss of BMD—mitochondrial toxicity induced
by NRTIs may be involved (as it is in other ART-
related adverse events like lactic acidosis and
lipodystrophy) [77]. Tenofovir may cause a
greater degree of initial BMD loss secondary to
urinary phosphate wasting and renal
osteodystrophy [78]. However, more research
is required to fully determine the prevalence,
causes, and consequences of these changes in
BMD.
Cardiac
There has not been a signal of increased
ischemic cardiovascular events in those
receiving TDF (as there is with some other
anti-retrovirals, e.g., abacavir, didanosine, and
certain PIs) in cohorts such as D:A:D [79].
Conversely, it has become apparent that TDF
has a lipid-lowering effect [15, 80], and though
this has beneficial effects on calculated
cardiovascular risk we are presently lacking
good data on actual influence on clinical
cardiac events.
TENOFOVIR ALAFENAMIDE (TAF)
Following recognition of the nephrotoxic
potential of TDF Gilead developed TAF, like
TDF a pro-drug of tenofovir, which is currently
being reviewed by regulatory agencies. TAF is
primarily metabolized to active tenofovir
within lymphoid cells and not plasma—
thereby decreasing systemic exposure to
tenofovir (as compared to TDF) while
maintaining high lymphoid intracellular
concentrations.
In HIV, TAF has been co-formulated into a
single-tablet regimen with
elvitegravir/cobicistat/emtricitabine (E/C/F/
TAF; Gilead Sciences, Inc.) and compared
against Stribild (elvitegravir/cobicistat/
emtricitabine/TDF; ClinicalTrials.gov number,
NCT01497899) [81]. Non-inferior virologic
control at week 48 was demonstrated (88.4%
and 87.9% of patients with HIV-RNA levels
\50 copies/ml, respectively). Furthermore,
these trials have shown a similar general safety
profile between the regimens and statistically
significant differences with respect to renal and
bone markers favoring TAF, though with a
decrease in apparent beneficial effects upon
lipid levels (potentially correlating with less
systemic tenofovir exposure with TAF vs. TDF).
Further studies are required to more fully
determine any beneficial influences of TAF
versus TDF (on toxicity and efficacy); whether
there are any detrimental impacts (such as
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potential decreases in TDF-related lipid-
lowering activity); and the optimal renal
monitoring (if any) required with this agent.
Overall, it is likely that TAF and TAF-
containing FDCs will supersede TDF in coming
years, although caution is required with respect
to any potential toxicities as yet unrevealed by
the development program.
CONCLUSIONS
With more than 7.5 million person-years of TDF
experience and many pivotal clinical studies,
tenofovir has proven to be a very effective and
generally safe drug. There are potential issues
related to renal dysfunction and BMD, however,
this medication has been a pivotal component
of successful anti-retroviral regimens for many
patients globally.
In the next few years, TDF will become
available as a generic drug in most parts of the
world, tenofovir is likely to find a niche in PrEP,
and the disoproxil formulation may be partly
superseded by TAF in Western nations. TAF is
also being made available to generic
manufacturers to allow the production of
affordable products in developing countries.
Tenofovir is therefore likely to remain of great
utility in HIV for many years to come.
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